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BACKGROUND: Established methods exist for evaluating the effects of uncertainty 
around the model structure and parameters on the results generated by traditional 
cost-effectiveness analyses (CEAs) and include one-way and probabilistic sensitivity 
analyses (SAs). In contrast to the primary outcome of a traditional CEA—the ICER—
the primary outcomes of a threshold CEA conducted for a product early in develop-
ment include (1) the value-based price opportunity given a hypothetical or target 
product proﬁ le and (2) the magnitude of effect required to justify a target price. 
Because the outputs of a threshold model pertain to a new drug or indication where 
little or no data have been collected, and because the outputs are multiple, representing 
the set of product attributes, including price, that will deﬁ ne drug value, there is a 
need to explore the sensitivity of the results to factors that go beyond uncertainty. In 
analyses that generate potential value-based price or product attribute levels, new 
methods and applications of SA are required. METHODS: We present example 
one-way and probabilistic SAs, highlighting problems in interpretation that arise when 
traditional sensitivity analyses are applied to threshold models. We propose alternative 
SA methods and analyses and present interpretations of results. a Pricing Contribution 
Diagram is presented as a means of characterizing the extent to which each product 
attribute (efﬁ cacy, safety, tolerability, quality of life, position in care pathway) inﬂ u-
ences the value-based price opportunity. Probabilistic SAs are presented to examine 
the relationship between price (value-based and target) and individual product attri-
butes, and the inﬂ uence of uncertainty in other model inputs. CONCLUSIONS: 
Traditional methods of conducting SA are insufﬁ cient when applied to the threshold 
application of CEA. Instead, SAs speciﬁ c to threshold models supporting decisions 
regarding early stage development should be employed.
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TWO APPROACHES TO ANALYZING LONGITUDINAL DATA WITH 
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Jo H1, Gemmen E2, Bharmal M2
1Quintiles, Parsippany, NJ, USA; 2Quintiles, Rockville, MD, USA
OBJECTIVES: To compare two statistical approaches for analyzing longitudinal data 
with missing observations: 1)imputation using Last Observation Carried Forward 
method (LOCF) and 2)Mixed-effects Model Repeated Measures method (MMRM) to 
analyze the change from baseline in health-related quality of life (HRQoL) by medica-
tion adherence level. METHODS: HRQoL via SF-12 Health Survey and medication 
adherence via a 5-level categorical response was measured monthly for one-year for 
184 patients in a U.S. multiple sclerosis observational study. HRQoL was summarized 
in two continuous variables: Physical Component Score (PCS-12) and Mental Com-
ponent Score (MCS-12). Categorically collected medication adherence was converted 
to numeric values and average compliance was calculated over a 1-year period then 
categorized into two groups: ≥90% (GT90) or <90% (LT90) compliant. For validity 
of compliance, patients who had completed at least 6 measurements during 1-year on 
compliance question were included. LOCF used the last available change from baseline 
to impute the missing values for early drop-out. MMRM is a likelihood-based 
approach which models all actual observations jointly, with no attempt at imputation 
for missing values. RESULTS: A total of 131 patients were included in this analysis. 
The 12-month change from baseline in PCS-12 comparing patients with GT90 compli-
ance vs. LT90 compliance using MMRM was 0.86 (p = 0.277) and using LOCF was 
1.30 (p = 0.339). For MCS-12, the improvement among patients with GT90 compli-
ance over LT90 compliance using MMRM was 2.04, while the corresponding 
improvement using LOCF was 1.97. For MCS-12, only the MMRM method produced 
statistically signiﬁ cant improvements (p-values: LOCF = 0.234, MMRM = 0.026). 
CONCLUSIONS: MMRM and LOCF yielded not only different results but also dif-
ferent statistical signiﬁ cance in the 12-month change from baseline in MCS-12. Since 
the approach to estimate and model is different between two methods, the pattern 
and shape of data must be investigated to ﬁ nd the right method to produce valid 
estimates.
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STATISTICAL DISTRIBUTIONS OF COST DATA IN PROBABILISTIC 
SENSITIVITY ANALYSIS
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OBJECTIVES: It is generally agreed that calculation of means after non-linear data 
transformations (e.g., log-transformation) does not result in a comparison of arithme-
tic means, and so is not appropriate for cost data in pharmacoeconomic evaluations. 
This would seem to preclude the use of log-normal distributions for cost data in 
probabilistic sensitivity analysis. The study objective was to investigate the statistical 
properties of arithmetic mean costs. METHODS: Monte Carlo simulations were use 
to investigate the statistical properties of arithmetic mean costs derived from an 
underlying log-normal distribution, loge (X) ~ N(m,s2), where m = loge(c10), s = 1.5 
(range 0.5 to 2.5). An underlying log-normal distribution was used because cost data 
are typically highly positively skewed. Microsoft Excel was used to perform the Monte 
Carlo simulations generating 1,000 arithmetic means, each from a sample of N = 100, 
for each value of s investigated. RESULTS: The distribution of arithmetic means 
increased in positive skewness as s increased. For s ≥ 1.5, the distribution of arithmetic 
means deviated considerably from normality. The level of skewness was greatly 
reduced by use of the log-normal distribution. The Gamma distribution was similar 
to the log-normal distribution in representing the distribution of arithmetic mean 
costs. CONCLUSIONS: Log-normal distributions for arithmetic mean cost data may 
have a role for use in probabilistic sensitivity analysis, although this needs further 
investigation using cost data derived from actual studies.
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EXAMINATION OF TYPE I AND II ERROR RATES IN INTENTION-TO-
TREAT RANDOMIZED EXPERIMENTS: DO SUBJECTS NEED TO STAY IN 
THE GROUP IN WHICH THEY WERE ASSIGNED?
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OBJECTIVES: Intention-To-Treat (ITT) analysis is an established method used in 
randomized experiments. However, analyzing data where crossover occurs (leaving 
subjects in the control or treatment arms when they have crossed from one group to 
another) prevents the true comparison of treatment and placebo effects. When sub-
ject’s crossover and ITT analysis methods are used, the true effect of the treatment 
cannot be determined as data from many groups are included with treatment. The 
purpose of this research is to determine Type I and II error rates computed by simula-
tion results with and without crossover. METHODS: A simulation study was con-
ducted to determine the impact of Type I and II error given six crossover percentages 
(1, 3, 5, 7, 9 and 11%), four effect sizes of treatment based on standard deviation (ES 
= 0.2, 0.4, 0.6 and 0.8 SD), and four sample sizes (n = 50, 100, 200 and 300). Simula-
tions were conducted using “R” and included 1,000 replications for each sample size, 
effect size and crossover combination. RESULTS: When ES were small (<0.2SD), Type 
I error rates were below 1%. When ES were larger, and crossover increased Type I 
rates increased above 4%. Large samples with high crossover and large ES had the 
highest Type I rates. Type II error rates, which are perhaps more critical, were higher. 
For 5% crossover, the Type II error rates were 2.4% and for 11% crossover 5.5%. 
When the ES are very large statistical signiﬁ cance can be observed regardless of 
crossover percent, even up to 11%. CONCLUSIONS: When crossover rates are low 
and ES are small, researchers can abandon ITT analysis methods and analyze samples 
as they were treated with little risk of additional Type I and II errors occurring. The 
beneﬁ t of “as-treated” analysis is that the true treatment effect can be determined with 
little risk of error. 
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Patient-Reported 
Outcomes Studies
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OBJECTIVES: Recent research suggests that the value of health depends also on the 
time of permanence in a health state. This would imply a more complex relationship 
between quality and quantity of life than the standard linear relationship assumed in 
the QALY model. To model whether and how life duration affects the value assigned 
to health states. METHODS: A discrete choice analysis study was conducted compris-
ing health-state scenarios added with a separate duration attribute. Health states were 
described with the EQ-5D (mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression), having 3 levels of severity each. Duration was introduced as a 
sixth domain with six levels (1, 5, 10, 15, 30, 50 years). Sixty choice sets were selected 
with a Bayesian approach (Stolk et al., Value in Health, 2010). a sample of 209 
undergraduate students self-completed the computerized response tasks. Data were 
analyzed with a conditional logistic regression model. RESULTS: Main effects show 
negative preferences towards problems with health domains and positive preference 
toward longer duration. However, preferences are not linearly related with duration 
(e.g., the next 41st year is valued less than the next 11th year), but a logarithm function 
describes more accurately this relationship. Negative interactions are found between 
health-states and duration. Trends of values for health states with increasing duration 
are represented by diverging curves: when duration increases, the value assigned to 
good states increases while the value assigned to bad states decreases. However, due 
to the logarithm relationship with duration, the marginal (negative or positive) value 
assigned to any state decreases as duration increases. CONCLUSIONS: Duration of 
health states interacts with the value assigned to them and inﬂ uences both direction 
and marginal values through the different durations. Our results show that reﬁ nement 
of the standard QALY framework can be amended.
